TMPRSS2 and COVID-19: To evaluate the potential of double-Tg mice to screen and develop therapeutic agents against COVID-19, we tested the TMPRSS2 inhibitor, nafamostat, whose inhibitory activity against SARS-CoV-2 infection is lost in the absence of TMPRSS217.